A detailed history of Ameriprise Financial Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 496,094 shares of NBIX stock, worth $67.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
496,094
Previous 413,172 20.07%
Holding current value
$67.2 Million
Previous $56.9 Million 0.41%
% of portfolio
0.01%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $9.5 Million - $12.7 Million
82,922 Added 20.07%
496,094 $57.1 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $1.02 Million - $1.12 Million
7,825 Added 1.93%
413,172 $56.9 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $2.66 Million - $2.93 Million
-20,400 Reduced 4.79%
405,347 $55.9 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $7.73 Million - $9.67 Million
-72,842 Reduced 14.61%
425,747 $56.1 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $153,816 - $191,575
-1,636 Reduced 0.33%
498,589 $56.1 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $4.08 Million - $4.78 Million
-45,599 Reduced 8.35%
500,225 $47.2 Million
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $5.44 Million - $7.11 Million
-57,776 Reduced 9.57%
545,824 $55.2 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $13.4 Million - $15.9 Million
-125,273 Reduced 17.19%
603,600 $72.1 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $4.82 Million - $5.64 Million
52,342 Added 7.74%
728,873 $77.4 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $11.7 Million - $15.5 Million
-154,930 Reduced 18.63%
676,531 $65.9 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $8.98 Million - $11.8 Million
124,005 Added 17.53%
831,461 $77.9 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $40.5 Million - $54.1 Million
508,925 Added 256.35%
707,456 $60.2 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $1.62 Million - $1.86 Million
18,798 Added 10.46%
198,531 $19 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $2.07 Million - $2.37 Million
-23,180 Reduced 11.42%
179,733 $17.5 Million
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $11 Million - $15 Million
125,387 Added 161.74%
202,913 $19.7 Million
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $22.5 Million - $28 Million
-258,713 Reduced 76.94%
77,526 $7.43 Million
Q3 2020

Nov 16, 2020

SELL
$96.16 - $135.15 $4.05 Million - $5.69 Million
-42,078 Reduced 11.12%
336,239 $32.3 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $1.12 Million - $1.72 Million
13,178 Added 3.61%
378,317 $47.2 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $1.94 Million - $2.95 Million
25,895 Added 7.63%
365,139 $31.5 Million
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $28.2 Million - $38.5 Million
325,055 Added 2290.89%
339,244 $36.6 Million
Q3 2019

Nov 14, 2019

SELL
$83.82 - $101.5 $1.05 Million - $1.27 Million
-12,475 Reduced 46.79%
14,189 $1.28 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $29,979 - $37,877
-415 Reduced 1.53%
26,664 $2.25 Million
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $1.6 Million - $2.11 Million
23,064 Added 574.45%
27,079 $2.39 Million
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $15,167 - $27,607
-222 Reduced 5.24%
4,015 $287,000
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $23,039 - $29,323
233 Added 5.82%
4,237 $521,000
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $1.34 Million - $1.89 Million
-17,802 Reduced 81.64%
4,004 $393,000
Q1 2018

May 15, 2018

SELL
$75.88 - $92.43 $6.38 Million - $7.77 Million
-84,079 Reduced 79.41%
21,806 $1.81 Million
Q4 2017

Feb 12, 2018

BUY
$58.53 - $77.59 $4.64 Million - $6.15 Million
79,244 Added 297.45%
105,885 $8.22 Million
Q3 2017

Nov 07, 2017

BUY
$47.97 - $61.28 $1.28 Million - $1.63 Million
26,641
26,641 $1.63 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.